# The INDORSE Study: Inhibition of Dipeptidyl Peptidase IV: Outcomes on Renal Sodium Excretion

> **NCT02406443** · PHASE4 · COMPLETED · sponsor: **University Health Network, Toronto** · enrollment: 36 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** Sitaglitpin
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02406443
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03
- **Primary completion:** 2016-06
- **Final completion:** 2017-01
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2018-04-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02406443

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02406443, "The INDORSE Study: Inhibition of Dipeptidyl Peptidase IV: Outcomes on Renal Sodium Excretion". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02406443. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*